Acceleron Pharma, a biopharmaceutical company, has appointed Kevin McLaughlin as senior vice president (SVP) and chief financial officer (CFO). McLaughlin has more than 30 years of financial and operating management experience spanning the biotech, high tech and education industries.
Most recently, he served as SVP and CFO of Qteros, a cellulosic biofuels company. From 1996 through 2007, he held several executive positions with Praecis Pharmaceuticals. He joined the company as its CFO, where he had responsibility for private financings, partnership financings, the company’s initial public offering (IPO) and subsequent secondary stock offerings. Later, McLaughlin became chief operating officer (COO), and then president and chief executive officer (CEO), as well as serving as a member of the board of directors. In this capacity he was responsible for negotiating the sale of the company to GlaxoSmithKline (GSK).
He began his career in senior financial roles at Prime Computer and Computervision Corporation. McLaughlin received a BS from Northeastern University and MBA from Babson College.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.